Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials

The decade of the 1990s was ripe with enthusiasm for the use of MMPIs to treat cancer. Limitations to new cytotoxic chemotherapy approaches to treat solid cancers and a better understanding of tumor biology provided a strong impetus for alternative drug development. It is estimated that the pharmaceutical industry invested at least a billion dollars in this effort. Because MMPIs represent an entirely different therapeutic modality from proven anti-cancer agents, many of the therapeutic trials designed to test MMPIs in human patients with cancer bypassed traditional approaches to evaluate drug efficiency. The concept of systematic progression from small phase I (dose escalation to toxicity to examine drug safety), to phase II (drug treatment of patients with cancer types considered to be good candidates for the selected drug), to phase III (randomized trial of new drug versus best available therapy to determine drug efficacy) trials was modified. Much to the chagrin of everyone involved in these studies, the randomized trials of MMPIs in advanced cancer have, pretty much, flopped. This review article will attempt to dissect out aspects of previous human and animal studies that may be helpful in making decisions about the future of MMPI drug development for the treatment of cancer. The important questions to be addressed in this report are: What are the lessons that we have learned from preclinical (animal models) and clinical studies of MMPIs in cancer? Are we ready to abandon MMPIs as a therapeutic modality in cancer (termination of phase III trials) or do we need to have a better understanding of the myriad effects of MMPs in cancer before we proceed to develop different types of drugs that alter MMP activity in patients with cancer (beginning of new phase I trials)?

[1]  G. Nicolson.  Tumor and host molecules important in the organ preference of metastasis. , 1991, Seminars in cancer biology.

[2]  Y. Li,et al.  Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. , 1998, Biochemistry.

[3]  H. Rochefort,et al.  Cellular localisation byin situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer , 2005, Breast Cancer Research and Treatment.

[4]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[5]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[6]  S. Zucker,et al.  Metastatic mouse melanoma cells release collagen-gelatin degrading metalloproteinases as components of shed membrane vesicles. , 1987, Biochimica et biophysica acta.

[7]  L. Liotta,et al.  Cancer cell invasion and metastasis. , 1992, Scientific American.

[8]  A. Rosemurgy,et al.  Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. , 1997, The Journal of surgical research.

[9]  R. Khokha.  Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. , 1994, Journal of the National Cancer Institute.

[10]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[11]  R. Fridman,et al.  Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. , 2002, Journal of the National Cancer Institute.

[12]  M. Klagsbrun,et al.  Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.

[13]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[14]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[15]  Takuma Sasaki,et al.  Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice , 1996, Cancer.

[16]  G. Giannelli,et al.  Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5 , 2000, The Journal of cell biology.

[17]  T. Morris,et al.  Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. , 1995, Cancer research.

[18]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Taraboletti,et al.  Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  S. Weiss,et al.  Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins , 1998, Cell.

[21]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[22]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[23]  D. Miles,et al.  Activity of type IV collagenases in benign and malignant breast disease. , 1993, British Journal of Cancer.

[24]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[25]  B. Nielsen,et al.  Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[26]  Y. Okada,et al.  Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis , 1995, Molecular and cellular biology.

[27]  T. Morris,et al.  Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA , 1999, British Journal of Cancer.

[28]  R. E. Luna,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. , 2000, Human pathology.

[29]  Z. Werb,et al.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter , 2000, Oncogene.

[30]  D. Cheresh,et al.  Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S Zucker,et al.  The Propeptide Domain of Membrane Type 1 Matrix Metalloproteinase Is Required for Binding of Tissue Inhibitor of Metalloproteinases and for Activation of Pro-gelatinase A* , 1998, The Journal of Biological Chemistry.

[32]  永川 裕一.  Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer , 2002 .

[33]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[34]  S. Loening,et al.  The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model , 2002, Oncogene.

[35]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[36]  A. Krüger,et al.  Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. , 2001, Cancer research.

[37]  S. Eccles,et al.  Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). , 1996, Cancer research.

[38]  I. Nishimoto,et al.  Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations , 1998, Clinical & Experimental Metastasis.

[39]  K. Hess,et al.  Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Brown.  Matrix metalloproteinase inhibitors , 2004, Breast Cancer Research and Treatment.

[41]  S. Nishimura,et al.  Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor , 1994, International journal of cancer.

[42]  R. Nagle,et al.  Cleavage of β4 Integrin by Matrilysin , 1997 .

[43]  S. Gruber,et al.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Foidart,et al.  In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy , 1998, The Journal of cell biology.

[45]  R. Greenwald.  Guidelines for Clinical Trial Design for Evaluation of MMP Inhibitors , 1994, Annals of the New York Academy of Sciences.

[46]  M. Hendrix,et al.  Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis , 1998, Clinical & Experimental Metastasis.

[47]  C. Sautès-Fridman,et al.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.

[48]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[49]  H. V. Van Wart,et al.  Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors , 1999, Nature Structural Biology.

[50]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. , 1996, Seminars in cancer biology.

[51]  T. Whiteside,et al.  Tumor-induced death of immune cells: its mechanisms and consequences. , 2002, Seminars in cancer biology.

[52]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[53]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[55]  N. Masumori,et al.  Inhibitory effect of minocycline on in vitro invasion and experimental metastasis of mouse renal adenocarcinoma. , 1994, The Journal of urology.

[56]  Y. Ma,et al.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. D’Armiento,et al.  Collagenase induction promotes mouse tumorigenesis by two independent pathways , 2000, Molecular carcinogenesis.

[58]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  A. Strongin,et al.  Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. , 2002, Cancer research.

[60]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[61]  R. Steele,et al.  Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. , 1996, British Journal of Cancer.

[62]  M. Bäckdahl,et al.  Gelatinase A, Membrane Type 1 Matrix Metalloproteinase, and Extracellular Matrix Metalloproteinase Inducer mRNA Expression: Correlation with Invasive Growth of Breast Cancer , 2000, World Journal of Surgery.

[63]  D. Scadden,et al.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[65]  A. Rosemurgy,et al.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[67]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[68]  K. Hirata,et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Y. Okada,et al.  Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. , 1997, Cancer research.

[70]  Charles D. McDermott,et al.  Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials , 1999, Annals of the New York Academy of Sciences.

[71]  L. Liotta,et al.  Immunohistochemical localization of matrix metallloproteinase 2 and its specific inhibitor timp‐2 in neoplastic tissues with monclonal antibodies , 1994, International journal of cancer.

[72]  M. Shipp,et al.  Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. , 1996, Cancer research.

[73]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Sledge,et al.  Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.

[75]  W. Stetler-Stevenson,et al.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.

[76]  R. Fife,et al.  Effects of Doxycycline on Cancer Cells in Vitro and in Vivo , 1998, Advances in dental research.

[77]  D. Leaper,et al.  Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging , 2000, The British journal of surgery.

[78]  P. Glynn,et al.  Expression of MMP‐2 and MMP‐9, their inhibitors, and the activator MT1‐MMP in primary breast carcinomas , 1999, The Journal of pathology.

[79]  E. Scanziani,et al.  Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. , 1995, Journal of the National Cancer Institute.

[80]  C. Gilles,et al.  Tumor Collagenase Stimulatory Factor (TCSF) Expression and Localization in Human Lung and Breast Cancers , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[81]  H. Friess,et al.  Human Macrophage Metalloelastase Worsens the Prognosis of Pancreatic Cancer , 2002, Annals of surgery.

[82]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[83]  P. Chambon,et al.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[84]  W. Bode,et al.  Structural features of a superfamily of zinc-endopeptidases: the metzincins. , 1995, Current opinion in structural biology.

[85]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[86]  T M Grogan,et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.

[87]  J. Fata,et al.  Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. , 1997, Blood.

[88]  H. Lijnen,et al.  Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). , 1998, Biochemistry.

[89]  Rongsong Li,et al.  EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. , 2000, Cancer research.

[90]  A. Gulino,et al.  Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen. , 2002, European journal of biochemistry.

[91]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  S Zucker,et al.  Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?: A Position Paper , 1999, Annals of the New York Academy of Sciences.

[93]  J. Fargnoli,et al.  Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. , 2001, Cancer research.

[94]  J. Nemunaitis,et al.  Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  Y. Okada,et al.  Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. , 1997, The Biochemical journal.

[96]  L. Matrisian,et al.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. , 1996, The American journal of pathology.

[97]  Charles D. McDermott,et al.  Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases , 1997, Clinical & Experimental Metastasis.

[98]  T. Whiteside,et al.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. , 1999, Cancer research.

[99]  James N Ingle,et al.  Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  R. Muschel,et al.  Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.

[101]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[102]  R. Dickson,et al.  The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  P. Brown.  Matrix metalloproteinase inhibitors , 1997, Angiogenesis.

[104]  D. Sheppard,et al.  The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1 , 2002, The Journal of cell biology.

[105]  J. Scholefield,et al.  Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial , 2002, British Journal of Cancer.

[106]  P. Black,et al.  Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. , 2001, Cancer research.

[107]  Jingsong Xu,et al.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.

[108]  M. Fini,et al.  Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. , 2000, The American journal of pathology.

[109]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[110]  P. Waterhouse,et al.  Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. , 1989, Science.

[111]  P. Davaris,et al.  Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. , 1999, Human pathology.

[112]  H. Miyake,et al.  Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  H. Zou,et al.  Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  M. Loriot,et al.  Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[115]  P. Bonomi.  Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. , 2002, Seminars in oncology.

[116]  R. Nagle,et al.  Synthetic matrix metalloproteinase inhibitor, BB‐94, inhibits the invasion of neoplastic human prostate cells in a mouse model , 1998, The Prostate.

[117]  G Murphy,et al.  Tissue inhibitors of matrix metalloendopeptidases. , 1995, Methods in enzymology.

[118]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[119]  S. Weiss,et al.  Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. , 1991, The Journal of clinical investigation.

[120]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[121]  C. Molloy,et al.  CHAPTER 6 – ROLE OF MATRIX METALLOPROTEINASES AND PLASMINOGEN ACTIVATORS IN CANCER INVASION AND METASTASIS: THERAPEUTIC STRATEGIES , 2002 .

[122]  D. Welch.  Technical considerations for studying cancer metastasis in vivo , 1997, Clinical & Experimental Metastasis.

[123]  G. Giannelli,et al.  Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. , 2002, Histology and histopathology.

[124]  J. Fata,et al.  Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line , 1998, Oncogene.

[125]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[126]  P. Watson,et al.  A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. , 2001, European journal of cancer.

[127]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[128]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[129]  A. Scorilas,et al.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients , 2001, British Journal of Cancer.

[130]  M. Bäckdahl,et al.  Correlation between stromelysin‐3 mRNA level and outcome of human breast cancer , 1994, International journal of cancer.

[131]  A. Matsushita,et al.  Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI‐166, on experimental pancreatic cancer , 2001, International journal of cancer.

[132]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[133]  S. Steinberg,et al.  Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  A. H. Drummond,et al.  Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.

[135]  W. Stetler-Stevenson,et al.  Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase a , 1995, International journal of cancer.

[136]  H. Moon,et al.  Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. , 2001, Cancer research.

[137]  L. Ding,et al.  Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.

[138]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[139]  R. Khokha,et al.  Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. , 1996, Oncogene.

[140]  R. Suzuki,et al.  Experimental metastasis is suppressed in MMP-9-deficient mice , 1999, Clinical & Experimental Metastasis.

[141]  R. Rees,et al.  Investigation of the effect of BB-94 (batimastat) on the colonization potential of human lymphoma cells in SCID mice. , 1996, Cancer letters.

[142]  S. Mousa,et al.  Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue , 2004, Clinical & Experimental Metastasis.

[143]  H. Augustin,et al.  Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. , 2001, Cancer letters.

[144]  R. Hoffman,et al.  Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. , 1994, Cancer research.

[145]  S. Eccles,et al.  A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops , 2002, International journal of cancer.

[146]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[147]  A. Rosemurgy,et al.  Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. , 2000, Cancer research.

[148]  F. Balkwill,et al.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. , 1993, Cancer research.

[149]  F. Orr,et al.  The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. , 2002, International journal of oncology.

[150]  Y. Okada,et al.  Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. , 1996, Cancer research.

[151]  E. Montgomery,et al.  Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma , 2006, Investigational New Drugs.

[152]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[153]  Nicolson Gl.  Tumor and host molecules important in the organ preference of metastasis. , 1991 .

[154]  R. Poulsom,et al.  Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. , 1998, The American journal of pathology.

[155]  I. Stamenkovic,et al.  CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.

[156]  Z. Marschall,et al.  Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines , 1998, Gut.

[157]  J. Nemunaitis,et al.  A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer , 2002, British Journal of Cancer.

[158]  B. Têtu,et al.  Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. , 1998, Human pathology.

[159]  R. Hruban,et al.  Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. , 2002, The American journal of pathology.

[160]  H. Guo,et al.  The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. , 1995, Cancer research.

[161]  W. Bode,et al.  Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. , 1995, Biochemistry.

[162]  Peter C. Brooks,et al.  New Functions for Non-collagenous Domains of Human Collagen Type IV , 2000, The Journal of Biological Chemistry.

[163]  R. Nagle,et al.  Cleavage of beta 4 integrin by matrilysin. , 1997, Experimental cell research.

[164]  R. Pierce,et al.  Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.

[165]  U. Sauer,et al.  Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. , 1999, Anticancer research.

[166]  I. Macdonald,et al.  The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells , 1999, Clinical & Experimental Metastasis.

[167]  G. Stamp,et al.  Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma , 1997, The Journal of pathology.

[168]  I. Hart,et al.  Matrix metalloproteinases and metastatic cancer. , 1998, Biochemical Society symposium.

[169]  L. Matrisian,et al.  The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. , 1998, Cancer research.

[170]  F. Cosset,et al.  Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors , 1999, Gene Therapy.

[171]  Y. Soini,et al.  72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[172]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[173]  Manuel Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2002, Hematology/oncology clinics of North America.

[174]  M. Löhr,et al.  Novel treatments and therapies in development for pancreatic cancer , 2002, Expert opinion on investigational drugs.

[175]  H. Friess,et al.  Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer , 1995, International journal of cancer.

[176]  A. Stoppacciaro,et al.  Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor , 1994, International journal of cancer.

[177]  N. Borkakoti.  Matrix metalloproteases: variations on a theme. , 1998, Progress in biophysics and molecular biology.

[178]  C. Wolf‐Peeters,et al.  Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. , 1997, The American journal of pathology.

[179]  K. O'Byrne,et al.  Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  S. Zucker,et al.  Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells. , 1987, Cancer research.

[181]  I. Macdonald,et al.  Preclinical Assessment of Anti-cancer Therapeutic Strategies using in vivo Videomicroscopy , 1998, Cancer and Metastasis Reviews.

[182]  J. Foidart,et al.  Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy , 2004, Virchows Archiv.

[183]  H. Friess,et al.  Role of MT‐MMPs and MMP‐2 in pancreatic cancer progression , 2000, International journal of cancer.

[184]  J. Foidart,et al.  Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. , 2002, Experimental cell research.

[185]  M. Rothenberg,et al.  New drugs on the horizon: matrix metalloproteinase inhibitors. , 1998, Stem cells.

[186]  Charles D. McDermott,et al.  Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[187]  Nils Brünner,et al.  Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[188]  L. Liotta,et al.  Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. , 1990, Cancer research.

[189]  C. Rossi,et al.  Inhibition of gelatinase A (MMP‐2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma , 1999, International journal of cancer.

[190]  R. Fridman,et al.  High Affinity Binding of Latent Matrix Metalloproteinase-9 to the α2(IV) Chain of Collagen IV* , 1998, The Journal of Biological Chemistry.

[191]  H. Rasmussen.  Batimastat and Marimastat in Cancer , 1999 .

[192]  S. Sheng,et al.  Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4 , 1997, Oncogene.

[193]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[194]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[195]  L. Golub,et al.  Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non‐antimicrobial tetracycline analog (COL‐3) in a metastatic prostate cancer model , 2002, International journal of cancer.

[196]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.